Lindbrook Capital, LLC Immuno Gen, Inc. Transaction History

Lindbrook Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$12.46 - $29.95 $5,183 - $12,459	416 Added 199.04%	625 $18,000
Q3 2023 Oct 25, 2023	BUY	$14.09 - $19.87 $211 - $298	15 Added 7.73%	209 $3,000
Q2 2023 Jul 28, 2023	BUY	$3.75 - $20.05 $727 - $3,889	194 New	194 $3,000
Q4 2022 Jan 24, 2023	BUY	$4.55 - $6.31 $1,087 - $1,508	239 Added 412.07%	297 $0
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $259 - $375	58 New	58 $0

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.